G-CSF: status quo and new indications.
Herrmann
F
F
Abt. Hämatologie/Onkologie, Kliniken der Universität, Freiburg, Germany.
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D016179:Granulocyte Colony-Stimulating Factor / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia / Q000628:therapy; D009190:Myelodysplastic Syndromes / Q000628:therapy; D009503:Neutropenia / Q000139:chemically induced / Q000628:therapy*
D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor